Perrigo (PRGO) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Zymeworks (ZYME) has outperformed Perrigo (PRGO) over the past year, gaining 60.8% versus a loss of 32.9%. Over five years, ZYME leads with a +2.3% price change compared with -67.5% for PRGO. Perrigo is the larger company by market cap ($2.01 billion vs $1.90 billion), about 1.1 times the size.
On valuation, Perrigo trades at a lower forward P/E (6.1x vs 30.4x for Zymeworks). Perrigo pays a dividend yielding 7.97%, while Zymeworks does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRGO | ZYME |
|---|---|---|
| Share price | $14.55 | $26.53 |
| Market cap | $2.01B | $1.90B |
| 1-day change | +3.93% | +3.43% |
| YTD return | +4.53% | +0.76% |
| 1-year return | -32.89% | +60.79% |
| 5-year return | -67.46% | +2.27% |
| Forward P/E | 6.07 | 30.43 |
| EPS (TTM) | $-12.28 | $-2.02 |
| Dividend yield | 7.97% | 0.00% |
| Annual dividend | $1.16 | $0.00 |
| 52-week high | $22.02 | $31.34 |
| 52-week low | $9.23 | $16.00 |
| Distance from 52-week high | -33.92% | -15.35% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +13.40% | +55.33% |
| Average volume | 2.81M | 673.06K |
| Shares outstanding | 138.37M | 71.20M |
| Employees | 8,100 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYME has outperformed PRGO by 93.7 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.97% vs 0.00%).
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
PRGO vs ZYME FAQ
Which is bigger, Perrigo or Zymeworks?
Perrigo (PRGO) is larger, with a market capitalization of $2.01B compared with $1.90B for Zymeworks (ZYME).
Which stock has performed better over the past year, PRGO or ZYME?
ZYME returned +60.79% over the past 12 months, compared with -32.89% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perrigo or Zymeworks?
Perrigo pays a dividend yielding 7.97%, while Zymeworks does not currently pay a regular dividend.
Are Perrigo and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.